HomeSGMO • NASDAQ
Sangamo Therapeutics Inc
add
$0.54
0.54%
Pre-market:(1.57%)+0.0085
$0.55
Closed: Aug 29, 4:02:51 AM UTC-4 · USD · NASDAQ · Disclaimer
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 18.31M | 5,042.13% |
Operating expense | 9.08M | -24.63% |
Net income | -19.99M | 44.68% |
Net profit margin | -109.18 | 98.92% |
Earnings per share | -0.08 | 53.33% |
EBITDA | -16.86M | 51.36% |
Effective tax rate | -0.14% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 38.34M | 38.00% |
Total assets | 97.56M | 4.89% |
Total liabilities | 77.96M | 12.45% |
Total equity | 19.60M | — |
Shares outstanding | 301.71M | — |
Price to book | 7.69 | — |
Return on assets | -48.59% | — |
Return on capital | -122.55% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -19.99M | 44.68% |
Cash from operations | -18.16M | 32.46% |
Cash from investing | -24.00K | -118.90% |
Cash from financing | 28.61M | 5,468.48% |
Net change in cash | 13.16M | 147.79% |
Free cash flow | -9.65M | 40.10% |
Previous close
$0.54
Day range
$0.54 - $0.56
Year range
$0.41 - $3.18
Market cap
163.32M USD
Avg Volume
6.73M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases. Wikipedia
CEO
Founded
1995
Headquarters
Website
Employees
183
